Jump to content

Phaeochromocytoma

From Surgopaedia

Epidemiology

[edit | edit source]
  • Affects about 0.2% of patients with HTN
  • Peak incidence between 40-50yo
  • Familial cases can manifest earlier and more often multifocal
  • '10%' axiom is not really true in modern times
    • Bilateral
    • Malignant
    • Extra-adrenal
    • Familial

Risk factors

[edit | edit source]
  • MEN 2 (50% penetrant)
  • VHL (10-20% penetrant)
  • NFT 1 (1-5% penetrant)
  • Germline mutations in succinate dehydrogenase (lifetime penetrance >75%)
    • See separate topic under 'oncology'


Pathophysiology

[edit | edit source]
  • Malignancy
    • 2.5-40% are malignant, depending on underlying phenotype
    • No histopathologic criteria exist for determining malignancy
    • Malignancy is defined by development of metastases (defined as distant implants in locations where neuroectodermal tissues are not normally found)
    • Most common metastatic sites are axial skeleton, lymph nodes, liver, lung and kidney
  • Paragangliomas
    • Tend to secrete noradrenaline rather than adrenaline


Presentation

[edit | edit source]
  • Classic triad - headache, diaphoresis, palpitations
    • Almost all patients will have at least one
  • HTN (90%) - can be episodic or sustained

Diagnosis

[edit | edit source]
  • Biochemical
    • Need to confirm elevated levels of catecholamines and their metabolites in body fluids. The exact profiles vary; tumours have different characteristics depending on their expression of synthetic and degradative enzymes.
    • Testing rationale
      • Plasma metanephrines/normetanephrines: sensitivity 99%, specificity 85%
        • Drawn in supine position, and after an overnight fast, avoiding caffeine and nicotine
      • 24-hour urine catecholamines and metabolites: specificity 99%
        • Considered positive when total metanephrines or any single catecholamine fraction is elevated above its cut-off value. This maintains high specificity and yields a sensitivity of about 88%.
      • Given that phaeochromocytoma is a rare diagnosis within a large pool of hypertensive patients, false-positives are a real problem, and specificity is crucial. It has been estimated that false-positives outnumber true positives by up to 30:1 when plasma metanephrines are used as screening.
    • Drugs and conditions that can cause elevated metanephrines:
      • Sympathomimetics
      • Phenoxybenzamine
      • Paracetamol
      • Psychotropic drugs including TCAs
      • Major physical or psychological stressors
    • Approach
      • Start with serum metanephrines
      • If positive, test urine
      • Clonidine suppression testing (give 0.3mg oral clonidine) can be used but is uncommonly needed
  • Anatomical localisation/staging
    • CT or MRI can be used - CT is often more useful, but MRI is slightly more sensitive
      • CT - characteristic - heterogenous with higher attenuation. All phaeos have HU > 10.
      • MRI - bright on T2
    • Scintigraphy with (131)I or (123)I-labeled metaiodobenzylguanidine (MIBG) can be performed when multifocal or malignant disease is suspected
      • Highly specific, but sensitivity only 77-90%
    • PET (F-DOPA) which somehow uses DOTATATE is developing as superior to MIBG, but apparently isn't widely available yet
  • Check for genetic syndromes
  • Histopathological
    • PASS score - composite of capsular or vascular invasion, mitotic rate, necrosis
    • GAPP - phaeos and paragangliomas - combines histopathological and clinical criteria - probably the more favoured score now

Differential diagnosis

[edit | edit source]
  • Hyperthyroidism
  • Hypoglycaemia
  • CAD
  • CCF
  • CVA
  • Drug effects
  • Panic disorder

Phaeochromocytoma in pregnancy

[edit | edit source]
  • Rare, but potentially fatal (29% mortality if diagnosed in labour or post-partum)
  • Adrenalectomy in second trimester
  • Postpone surgery until after delivery if diagnosed in third trimester

Treatment approach

[edit | edit source]
  • Surgical resection of primary and metastatic lesions, which can also have palliative responses in the absence of a cure, due to reducing the systemic impact of catecholamine release
  • Malignant tumours are minimally responsive to radiotherapy and chemotherapy
    • I-MIBG radionuclide therapy has a 22% complete or partial response rate, with significant toxicities and questionable long-term benefit
  • Chronic medical management can be achieved with alpha1-adrenergic blockers

Surgery

[edit | edit source]
  • Minimise tumour manipulation, avoid rupture
  • Tumours tend to be highly vascular and adherent to adjacent structures
  • Mostly can be removed laparoscopically, but prefer open with signs of local invasion or tumours >6cm

Peri-op care

[edit | edit source]
  • Pre-op care
    • Start with phenoxybenzamine 10mg BD (alpha-adrenergic blockade) as soon as the biochemical diagnosis is made
      • This drug is a non-specific, non-competitive (irreversible), long-acting (half-life 24 hours), alpha-adrenergic antagonist
      • Side effects postural hypotension and nasal congestion (which can actually serve as a useful indicator of adequate blockade)
      • Other options would be prazosin or doxazosin
    • Titrate upwards every 2-3 days to a maximum of 40mg TDS to achieve normalisation of HR and BP
    • Calcium channel blockers can be added if this is inadequate BP control after titration
    • Beta blockers can be added with persistent tachycardia
    • Pre-op conditioning should last at least two weeks to allow adequate reversal of alpha-adrenergic receptor down-regulation. This restores sensitivity to vasopressor agents, which can then be used to treat the patient post-operatively.
    • Pre-operative volume repletion is generally not indicated - once blockade is achieved, patients can restore volume by drinking to thirst
    • Needs pre-op staging
  • Intra-op HTN
    • Caused by stimulation of catecholamine release by induction agents, along with direct manipulation of the tumour
    • Intra-operative alpha-adrenergic blockade followed by aggressive volume repletion and alpha-adrenergic agonists in the immediate post-op period
    • Art-line is required
    • Pause for 10 mins if BP getting very high
    • Ligate vein before arteries
  • Post-op HTN
    • Can be profound - state of hypovolaemia created by the presence of excess circulating catecholamines. Sudden withdrawal leads to peripheral arteriolar vasodilation and a dramatic increase in venous capacitance, which together may precipitate CV collapse.
    • Aggressively resuscitate if hypotension or oliguria occurs
    • Vasopressors may be required

Prognosis

[edit | edit source]
  • Surgery is curative in >90% of cases

Indications for genetic testing

[edit | edit source]
  • Age <45yo
  • Multiple tumours
  • Head and neck paraganglioma